The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
C07C 303/32 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical products for the prevention and treatment of cancer; dermatological pharmaceutical products; pharmaceutical products for ophthalmological use; pharmaceutical products for the treatment of joint disease; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; intravenous bags, syringes, and vials sold filled with injectable pharmaceutical preparations, namely, oncologic products and ancillary products, chemotherapy agents, anti-emitics, and anti-infectives; anticholinergics; anticholinesterases; anti-hypotensives; biological preparations for the treatment of cancer; anesthetics for surgical and non-surgical use; antibiotics; antiemetics; analgesics; sedatives; dietary supplements; vaccines; blood for medical purposes; all of the foregoing featuring differentiated packaging for the purpose of reducing user errors and promoting correct medication selection.
3.
THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL, A P-GP INHIBITOR, AND A CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMORS
The application pertains to pharmaceutical combinations of orally administered paclitaxel, a P-gp inhibitor, and a checkpoint inhibitor. The pharmaceutical combinations are suitable for the treatment of a cancer (e.g., lung cancer) in a subject.
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of bags sold filled with intravenous fluids used for the delivery of pharmaceutical preparations; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged pharmaceutical preparations in the nature of anticholinergics, anticholinesterases, anti-hypotensives, anesthetics, antibiotics, antiemetics, and sedatives; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged pharmaceutical preparations, intravenous bags filled with pharmaceuticals, syringes filled with pharmaceuticals, and vials filled with pharmaceuticals, with all of the aforementioned containing oncologic products and ancillary products, chemotherapy agents, anti-emitics, anti-infectives, anticholinergics, anticholinesterases, anti-hypotensives, biologicals, anesthetics for surgical and non-surgical use, antibiotics, and sedatives; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged biological preparations for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, joint, cardiovascular, cardiopulmonary, oncological, neurological, gastrointestinal, hormonal, psychiatric and immune system related diseases and disorders and cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of bags sold filled with intravenous fluids used for the delivery of pharmaceutical preparations; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged pharmaceutical preparations in the nature of anticholinergics, anticholinesterases, anti-hypotensives, anesthetics, antibiotics, antiemetics, and sedatives; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged pharmaceutical preparations, intravenous bags filled with pharmaceuticals, syringes filled with pharmaceuticals, and vials filled with pharmaceuticals, with all of the aforementioned containing oncologic products and ancillary products, chemotherapy agents, anti-emitics, anti-infectives, anticholinergics, anticholinesterases, anti-hypotensives, biologicals, anesthetics for surgical and non-surgical use, antibiotics, and sedatives; printed paper labels to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of packaged biological preparations for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, joint, cardiovascular, cardiopulmonary, oncological, neurological, gastrointestinal, hormonal, psychiatric and immune system related diseases and disorders and cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Labeled syringe caps to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of syringes filled with pharmaceutical preparations for the treatment and prevention of viral diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, psychiatric diseases and disorders, immune system diseases and disorders, cancer, joint disease, respiratory diseases and disorders, allergies, and asthma; labeled port caps to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of intravenous bags filled with pharmaceutical preparations for the treatment and prevention of viral diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, psychiatric diseases and disorders, immune system diseases and disorders, cancer, joint disease, respiratory diseases and disorders, allergies, and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Labeled syringe caps to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of syringes filled with pharmaceutical preparations for the treatment and prevention of viral diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, psychiatric diseases and disorders, immune system diseases and disorders, cancer, joint disease, respiratory diseases and disorders, allergies, and asthma; labeled port caps to reduce user error and assist with the correct selection of medication and medical products, sold as an integral component of intravenous bags filled with pharmaceutical preparations for the treatment and prevention of viral diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, neurological diseases and disorders, gastrointestinal diseases and disorders, dermatological diseases and disorders, hormonal diseases and disorders, psychiatric diseases and disorders, immune system diseases and disorders, cancer, joint disease, respiratory diseases and disorders, allergies, and asthma
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations and drugs for use in the
treatment of cancer; pharmaceutical preparations and drugs
for use in chemotherapy; pharmaceutical preparations and
drugs for use in the field of oncology and immuno-oncology;
pharmaceutical preparations and drugs for use in the
treatment of oncological diseases and disorders; tumor
suppressing pharmaceutical preparations and drugs;
pharmaceutical products for the prevention and treatment of
cancer; chemotherapeutic drugs; pharmaceutical preparations
and drugs for the treatment of metabolic diseases and
disorders; pharmaceutical preparations for use in
dermatology; pharmaceutical preparations for use in the
treatment of skin disorders, skin aliments and skin
conditions; pharmaceutical preparations and substances for
the treatment of damaged skin and tissue. Providing information via a global computer network on the
research and development of drugs for the treatment of
cancer which involves the use of a pharmaceutical drug
platform that facilitates the absorption of anti-cancer
drugs; providing information relating to research and
development of drugs for the treatment of cancer.
The disclosure pertains to methods of treating and/or preventing psoriasis, comprising administering a therapeutically effective amount of KX-01, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing information via a global computer network on the research and development of drugs for the treatment of cancer which involves the use of a pharmaceutical drug platform that facilitates the absorption of anti-cancer drugs; providing information relating to research and development of drugs for the treatment of cancer
13.
Biaryl piperidine amide compounds and methods of use thereof
The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07C 233/13 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/22 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
15.
BIARYL PIPERIDINE AMIDE COMPOUNDS AND METHODS OF USE THEREOF
The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, (I), to a subject in need thereof.
The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
C07C 303/32 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
19.
BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE
The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
20.
Biaryl compositions and methods for modulating a kinase cascade
The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07C 233/13 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/22 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
C07C 303/32 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
24.
Compositions and methods for modulating a kinase cascade
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
C07D 211/82 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 413/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
25.
Bicyclic compositions and methods for modulating a kinase cascade
The invention relates to compounds of the class of 2-carboxamide substituted indoles and methods for modulating one or more components of a kinase cascade. The compounds of the invention are useful for osteoporosis, hepatitis B, opthalmic disease, diabetes, athrosclerosis, obesity, chronic neuropathic pain, and stroke.
